Združene države Amerike - angleščina - NLM (National Library of Medicine)

allergy laboratories, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10) - cynodon dactylon pollen 10000 [bau] in 1 ml -       standardized grass pollen extracts are used for the diagnosis and treatment of allergic disease to grass pollen. the standardized (bioequivalent allergy unit) extract in these vials is designed primarily for the physician equipped to prepare dilutions and mixtures as required. standardized grass pollen extracts l a beled in bau/ml are not interchangeable with grass pollen extracts labeled in au/ml or with non-standardized (weight/volume) grass pollen extracts. patients being switched from other types of extracts to allergy laboratories should have their dose adjusted. diagnosis of allergic disease to these grasses is made through a combined medical history sufficiently complete to identify allergic symptoms to grass pollen and identification of grass allergy by diagnostic skin testing. it is recommended that diagnostic skin testing (scratch or puncture) be performed with 10,000 bau/ml grass pollen extracts before testing with 100,000 bau/ml grass pollen extracts. 10,000 bau/ml and 100,000 bau/ml gras

Združene države Amerike - angleščina - NLM (National Library of Medicine)

allermed laboratories, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10) - cynodon dactylon pollen 10000 [bau] in 1 ml - standardized grass pollen extract is indicated for use in the diagnosis of grass allergy in patients with a history of allergic symptoms that occur during grass pollination. skin tests with standardized grass pollen extract should be done first by the puncture method using 10,000 bau/ml extract. if these tests are negative, they may be repeated by the puncture method with 100,000 bau/ml extract, or by the intradermal method using an appropriate dilution (see dosage and administration). the extract also is indicated for use in the treatment of allergic symptoms by immunotherapy in patients with a history of grass pollen allergy and established sensitivity to grass pollen extract by skin testing. the availability of 10,000 and 100,000 bau/ml extracts facilitates dose selection for safe switching to standardized grass pollen extracts. previously untreated patients should be initially treated with appropriately diluted 10,000 bau/ml. if tolerated, higher doses may be indicated. the use of grass pollen extract for

Združene države Amerike - angleščina - NLM (National Library of Medicine)

alk-abello, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10) - cynodon dactylon pollen 10000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

Združene države Amerike - angleščina - NLM (National Library of Medicine)

antigen laboratories, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), carya illinoinensis pollen (unii: pyo4jr720y) (carya illinoinensis pollen - unii:pyo4jr720y), carya tomentosa pollen (unii: g2a764t54b) (carya tomentosa pollen - unii:g2a764t54b), amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), rumex acetosella pollen (unii: n52miq - cynodon dactylon pollen 16 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

Združene države Amerike - angleščina - NLM (National Library of Medicine)

antigen laboratories, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10) - cynodon dactylon pollen 10000 [bau] in 1 ml - indications and usage     allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to grass allergens. confirmation is determined by skin testing. 10,000 bau/ml extracts are intended for percutaneous testing. if negative, 100,000 bau/ml products can be used for percutaneous test. dilutions made from 10,000 bau/ml products are indicated for immunotherapy of previously untreated patients. if 10,000 bau/ml product is tolerated and symptoms persist, dilutions made from 100,000 bau/ml can be administered. standardized grass pollen extracts labeled in bioequivalent allergy units (bau/ml) are not interchangeable with grass pollen extracts labeled in allergy units (au/ml) or with non-standardized grass pollen extracts. contraindications     do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of underly

Filipini - angleščina - FDA (Food And Drug Administration)

cyno sure healthcare inc - clotrimazole - tablet, vaginal - 100mg

Bangladeš - angleščina - DGDA (Directorate General of Drug Administration)

deeplaid pharmaco ltd. (homoeo) - cynodon (durba) - liquid

Bangladeš - angleščina - DGDA (Directorate General of Drug Administration)

s.b. homoeo laboratory - cynodon (durba) - liquid

Bangladeš - angleščina - DGDA (Directorate General of Drug Administration)

the homoeo research laboratory (bd) ltd. - cynodon (durba) - liquid

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.